Open-Label Lesinurad Monotherapy Extension Study in Gout

Inclusion Criteria: * Subject is able to understand the study procedures and the risks involved and is willing to provide written informed consent before the first study related activity. * Subject completed the double-blind treatment period in Study RDEA594-303 and was actively receiving and tolerating study medication (lesinurad or placebo) at Month 6 visit. * Subject is willing to adhere to the visit/protocol schedules. * Subject is male or female; female subjects of childbearing potential must agree to use an effective non-hormonal method of birth control during the study and for at least 14 days after the last dose of study medication. Exclusion Criteria: * Subject has any other medical or psychological condition, which in the opinion of the Investigator and/or the Medical Monitor, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements or to complete the study. * Subject has a past medical history of urolithiasis, nephrolithiasis, or kidney stone diathesis. * Subject developed kidney stones during Study RDEA594-303